Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and...

Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and set a December 20 target date to complete its regulatory review. The company's seeking approval of the the cholesterol-reducing fish-oil pill as an adjunct to diet for the treatment of high triglycerides with mixed dyslipidemia. Shares +6.2% in pre-market trading.

Vascazen was actually commercialized before Vascepa was on the market. Vascazen is commercialized as a Medical Food to correct an Omega-3 deficiency in Cardiovascular patients, so it deals with a broader patient population than Vascepa or Lovaza.

Just thought the Seeking Alpha readers would be interested in hearing about another prescription only Omega-3 therapy.

A Medical Food is a class of products, regulated by the FDA. Vascazen is only available by prescription and is specifically formulated for Cardiovascular patients that are deficient in Omega-3, which is unlike dietary supplements made for the "general population".

The clinical data on Vascazen is being presented at the AHA, ATVB meeting next week.